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Self-reported side effects of breast cancer treatment: a cross-sectional study
of incidence, associations, and the influence of exercise
Abstract
Purpose Side effects as a result of breast cancer treatment may have a lasting detrimental impact on quality of
life. Exercise has been shown to be an effective intervention in post-treatment care. This study aimed to gain a
better understanding of breast cancer treatment-related side effects through identifying potential patient
characteristic associations, including current levels of exercise.
Methods Four hundred and thirty-two breast cancer patients completed an online survey covering their
treatment and demographic background, current exercise levels, and self-reported treatment side effects. Side
effects were considered in a binary logistic regression against age, surgery, currently undergoing treatment, and
exercise levels to ascertain significant relationships (p < 0.05) and associative values (Odds Ratio).
Results Lumpectomy patients were less likely to report aching muscles (OR 0.61, 95 % CI 0.39-0.96), hot
flushes (OR 0.60, 95 % CI 0.38-0.96), and weight gain (OR 0.59, 95 % CI 0.38-0.92) than mastectomy
patients. Women currently undergoing treatment were more likely to report hot flushes (OR 3.77, 95 % CI
2.34-6.08), aching muscles (OR 1.62, 95 % CI 1.02-2.57), and weight gain (OR 1.89, 95 % CI 1.19-2.99) than
women finished treatment. Sedentary women were more likely to experience shoulder limitations (OR 1.77,
95 % CI 1.14-2.77), muscular chest wall pain (OR 1.69, 95 % CI 1.07-2.65), weight gain (OR 2.29, 95 % CI
1.44-3.64), lymphedema (OR 1.68, 95 % CI 1.04-2.71), and breathlessness (OR 2.30 95 % CI 1.35-3.92) than
their physically active counterparts.
Conclusions Patient characteristics may inform interventions to improve care post-breast cancer treatment.
Sufficient levels of exercise were consistently associated fewer side effects and should be encouraged.
Keywords
side, reported, self, associations, incidence, exercise, study, influence, sectional, cross, treatment, cancer,
breast, effects
Disciplines
Medicine and Health Sciences | Social and Behavioral Sciences
Publication Details
Gho, S. A., Steele, J. R., Jones, S. C. & Munro, B. J. 2013, 'Self-reported side effects of breast cancer treatment:
a cross-sectional study of incidence, associations, and the influence of exercise', Cancer Causes and Control,
vol. 24, no. 3, pp. 517-528.
This journal article is available at Research Online: http://ro.uow.edu.au/smhpapers/821
1 
 
Manuscript Title: Self-reported side-effects of breast cancer treatment: A cross-sectional 
study of incidence, associations, and the influence of exercise 
 
Authors: Sheridan A. Gho1; Julie R. Steele 1; Sandra C. Jones2; and Bridget J. Munro1 
1Biomechanics Research Laboratory, University of Wollongong, Wollongong, Australia 
2Centre for Health Initiatives, University of Wollongong, Wollongong, Australia 
 
 
Corresponding author: Sheridan A. Gho, BSc(Hons), School of Health Sciences, University 
of Wollongong, Wollongong, NSW 2522, Australia;  
Ph: (+61) 02 4221 4480;  

















Purpose: Side-effects as a result of breast cancer treatment may have a lasting detrimental 
impact on quality of life. Exercise has been shown to be an effective intervention in post 
treatment care. This study aimed to gain a better understanding of breast cancer treatment-
related side-effects through identifying potential patient characteristic associations, including 
current levels of exercise. 
Methods: 432 breast cancer patients completed an online survey covering their treatment and 
demographic background, current exercise levels, and self-reported treatment side-effects. 
Side-effects were considered in a binary logistic regression against age, surgery, currently 
undergoing treatment and exercise levels to ascertain significant relationships (p < 0.05) and 
associative values (Odds Ratio). 
Results: Lumpectomy patients were less likely to report aching muscles (OR 0.61, 95% CI 
0.39-0.96), hot flushes (OR 0.60, 95% CI 0.38-0.96) and weight gain (OR 0.59, 95% CI 0.38-
0.92) than mastectomy patients. Women currently undergoing treatment were more likely to 
report hot flushes (OR 3.77, 95% CI 2.34-6.08), aching muscles (OR 1.62, 95% CI 1.02-2.57) 
and weight gain (OR 1.89, 95% CI 1.19-2.99) than women finished treatment. Sedentary 
women were more likely to experience shoulder limitations (OR 1.77, 95% CI 1.14-2.77), 
muscular chest wall pain (OR 1.69, 95% CI 1.07-2.65), weight gain (OR 2.29, 95% CI 1.44-
3.64), lymphedema (OR 1.68, 95% CI 1.04-2.71) and breathlessness (OR 2.30 95% CI 1.35-
3.92) than their sedentary counterparts.  
Conclusions: Patient characteristics may inform interventions to improve care post breast 
cancer treatment. Sufficient levels of exercise were consistently associated fewer side-effects, 





Primary treatment following a breast cancer diagnosis is surgery. Post-surgery, many women 
will also undergo radiotherapy, together with systemic adjuvant therapies, including 
chemotherapy, hormonal or endocrine therapy, or a combination of these. Although 
increasingly effective in terms of disease control, negative side-effects of these breast cancer 
treatments are common [1]. These side-effects are often treatment specific and manifest in a 
range of symptoms. Local complications such as pain or numbness in the breast or chest wall, 
restricted arm motion, arm lymphedema, and skin sensitivity are worse with more extensive 
surgery, more extensive radiation, or both [2, 3]. Compounding these local complications are 
common side-effects of systemic adjuvant therapy including vasomotor symptoms such as 
hot flushes; neuropsychiatric symptoms such as a lack of energy or fatigue; gastrointestinal 
symptoms such as weight gain and nausea; and gynecological symptoms such as breast 
sensitivity or tenderness [4]. In some cases, these side-effects can become a major cause of 
morbidity and treatment discontinuation, and may have prolonged negative effects on a breast 
cancer survivor’s quality of life (QOL) [1, 4]. 
 Breast cancer treatment side-effects have been shown to impact upon QOL 
dimensions, suggesting that reducing these side-effects will have a positive effect on QOL 
[1]. Greater side-effects during breast cancer treatment have also predicted greater post-
treatment distress [5]. For example, fatigue as a treatment effect has emerged as a strong 
predictor of QOL within one year of treatment, and may continue to compromise QOL as 
long as five years post diagnosis [6, 7]. Impairments in upper body functioning as a result of 
breast cancer treatment have also been significantly related to reductions in QOL [8, 9]; and 
experiencing persistent arm lymphedema is related to worse general mental health and 
physical function [1]. It has been suggested that all currently available endocrine therapies 
have side-effect profiles that can affect patient-related QOL outcomes [10]. 
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 Compounding the detrimental impact side-effects have on QOL, unpleasant side-
effects as a result of taking medication are also significantly predictive of adherence to 
medication plans [4, 11]. Breast cancer treatment side-effects as a reason for non-adherence 
provides a compelling argument to better understand the mechanisms of these adverse events, 
as restricting or cessation of treatment could severely diminish opportunities for health gains. 
It is expected that better management of treatment-related side-effects may trigger a “cascade 
effect”, through improving QOL outcomes, in turn improving medication adherence, and 
ultimately resulting in better patient outcomes [4]. 
 Exercise is one of the most effective interventions that can assist in the management 
of breast cancer treatment side-effects through enhanced improvements in cardio-respiratory 
fitness, immune function during recovery, self-esteem and other psychological health 
parameters [12-14]. Breast cancer patients who exercise have reported decreased levels of 
anxiety and depression, and research reviews have also suggested physical activity during 
treatment and recovery may enhance breast cancer survival [15, 16]. Despite the well-
established benefits of exercise, the effect of exercise on a broader range of breast cancer 
treatment side-effects is generally unknown. Review authors have therefore called for more 
attention to be focused on how exercise affects the multitude of frequently experienced, 
persistent side-effects of breast cancer treatment [13, 14]. 
 Given the potential negative impact on QOL and prognosis, a better understanding of 
the prevalence of patient-determined side-effects is warranted, and the association of patient 
characteristics with these side-effects should be explored. Some studies have suggested that 
the experience of breast cancer treatment side-effects may vary as a function of age, stage of 
disease, and body mass index [17]; whereas other studies have suggested that socio-
demographic characteristics generally do not help identify women who will have greater or 
lesser symptom experience [1, 6, 18]. Patient characteristics may provide a useful initial step 
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towards developing intervention strategies to improve care for women living with a breast 
cancer diagnosis. 
Intervention strategies involving exercise have been identified as being effective, and 
further investigation into the influence of exercise on a wider range of breast cancer treatment 
side-effects is required. Therefore, the purpose of this study was to gain a better 
understanding of breast cancer treatment side-effects through identifying potential patient 
characteristic associations with age, type of surgery, currently undergoing treatment and 
levels of exercise. We hypothesised that (i) patient characteristics would hold moderate 
associative values for side-effect experience; and (ii) higher exercise levels would be 
associated with a lesser side-effect experience. 
Participants and Methods 
Participants and Survey Implementation 
Breast cancer patients who had a registered email address with the Breast Cancer Network 
Australia (BCNA) Review and Survey group or the Cancer Councils of Victoria or Western 
Australia were invited by email to complete an online survey. Inclusion criteria were any 
women, over 18 years of age, with a breast cancer diagnosis prior to the survey distribution 
date.  The survey invitation contained a brief introduction to the investigators and the study, 
as well as a direct link to the uniform resource location (URL) containing the internet-based 
survey. The URL was open to responses for 4 months, and closed when continued promotion 
of the survey did not illicit any further responses. Due to the anonymity of the data collection 
procedures, and the ‘sharing’ nature of the internet, the survey’s response rate could not be 
tracked. However, of the 482 women who visited the initial URL, 432 completed the survey 
(89.6% completion rate). Participant informed consent was obtained whereby the first page of 
the survey was a participant information sheet to which participants clicked “I agree” in order 
to progress with the online survey. The University Human Research Ethics Committee 
approved all data collection procedures (HREC08/326). 
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Online Survey Instrument 
The online survey instrument was based on a previously validated paper-based questionnaire 
[19]. To validate the online version, seven focus groups with breast cancer patients were 
conducted (total participants = 20) at community centers around the greater Sydney area. 
During these groups, the think-aloud technique was employed [20] and participants were 
queried about their understanding, and about the relevance and sensitivity of each question 
which lead to changes to facilitate the participants’ understanding and ease in navigating the 
electronic version. 
The final survey instrument included 68 closed-ended and 11 open-ended items 
covering background variables such as health status, location, disease timelines, treatment 
methods, surgery types, treatment complications, and each respondent’s current exercise 
habits. Duplicate surveys were prevented by firstly checking internet protocol (IP) addresses 
embedded in the responses, and secondly reviewing the respondent’s date of birth.  No 
identical IP addresses were submitted, and checking responses from women with the same 
date of birth also indicated no duplicates. 
Independent Analytical Variables 
Age: Participant age was an open-ended response to “What is your date of birth?”, calculated 
with respect to the survey submission date (providing age at time of survey completion). 
Following this calculation, participants were split into categories of being “Under 50 years 
old”, or “50 years and over” for the purpose of the binary logistic regression (see Table 1). 
Surgery Type: Participant surgery type was assessed by a closed-ended question for which 
the responses were either a lumpectomy or mastectomy of either the right or left breast. 
Responses were presented in a 2 x 2 button grid (lumpectomy and mastectomy by left and 
right breast) and were not mutually exclusive, permitting participants to indicate if they had 
undergone surgery on both breasts, or had a lumpectomy, followed by a mastectomy. Women 
were instructed to skip the question if they had not undergone surgery. Only three 
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participants did not respond with a surgery type. Participants were then grouped into 
categories of a “Lumpectomy” or a “Mastectomy” for the binary logistic regression (see 
Table 1). 
Current Treatment: Participants were asked “Are you CURRENTLY undergoing any of the 
following treatments for your breast cancer?” with closed-ended response categories of 
chemotherapy, radiotherapy and hormonal treatment.  Examples of hormonal treatments were 
provided, and responses were not mutually exclusive. Women were also asked the date of 
their last treatment ever if they had finished these categories of treatment. The difference 
between the survey completion date, and treatment completion date was calculated to give a 
time since treatment completion, which is summarised in Table 1. For the purpose of the 
binary logistic regression, participants were divided into categories of “current treatment” vs. 
“finished treatment”. 
Exercise: The Recreational Activities domain of the Global Physical Activity Questionnaire 
Version 2 (GPAQ2) [21] was used to assess recreational exercise intensity and duration. The 
GPAQ2 calculates metabolic equivalents (METs) to express the intensity of reported physical 
activities [21]. The total time spent in physical activity during a typical week, the numbers of 
days, as well as the intensity of the physical activity are taken into account to calculate three 
categorical indicators (low, moderate, and high). The criteria for these levels are shown in 
Table 2, along with the number of women who met each criterion, and the percentage these 
women formed of the total sample. For the purpose of the binary logistic regression, all 
women meeting either the moderate or high levels of exercise (n = 158) were classified as 
“sufficiently active”.  
Dependent Analytical Variables 
Breast Cancer Treatment Side-effects: Side-effects were reported as those experienced in the 
two weeks prior to completing the survey, and were evaluated by a closed-ended list of 
possible complications (see Table 3). Participants were asked to respond regarding their 
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experience of that side-effect on a 5-point Likert scale (from none to severe; see Table 3). For 
the purpose of binary logistic regressions, women were divided into categories of “no 
symptom experience” (Likert response = 1) vs. “any level of experience” (Likert response = 
2-5).  
Statistical Analysis 
Descriptive Analysis: Answers to the closed-ended side-effects items were coded and 
counted to determine the frequency response for each item. The number of responses to 
different questions may vary as respondents were given the option to skip questions to 
minimise participant burden. Study population proportions were then calculated as a 
percentage of the number of women who answered that question. To provide an accurate 
representation of the data, non-responses were not assumed to represent not experiencing a 
particular side-effect, but rather data were analyzed based only on the women who provided a 
response to that question. The mean of responses for each side-effect question was also 
calculated to show where most participants responded on the continuum of not experiencing 
that particular side-effect to experiencing it severely. The closer the mean score was to ‘5’, 
the more severely participants experienced that side-effect. 
Relationship Analysis (Binary Logistic Regression Model): Each side-effect was considered 
in a binary logistic regression to ascertain any associated variables and significant 
relationships. Whether a participant reported experiencing a side-effect (none vs. any level of 
experience) was inserted as a dependent variable against the independent variables of age (< 
50 years vs. ≥ 50 years), type of surgery (lumpectomy vs. mastectomy), currently undergoing 
treatment (current vs. finished treatment), and exercise levels (not sufficiently active vs. 
sufficiently active). This method of analysis has been successfully used in a previous cross-
sectional survey data with a breast cancer population [22], and ensures each independent 
variable is analysed while controlling for the other three independent variables. All statistical 
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Participants were 432 female breast cancer patients and survivors aged 23-77 years (mean 
53.3 ± 9.8 years). Table 1 provides information on the participant’s characteristics with 
comparisons to Australia population data.  In brief, the self-reported health status of the 
survey sample was comparable to that of the general Australian female population; and the 
survey sample was spread across Australian States and Territories in similar proportions to 
the wider breast cancer population, with the exception of the Australian Capital Territory, 
which formed 10% of the sample and only 2% of the national spread. The age spread of the 
sample was generally lower than the age of the wider Australian breast cancer population, 
which may skew results towards a younger breast cancer population. The proportion of 
women deemed sufficiently active in the survey sample was very comparable to an age-
matched general Australian female population (37.4% vs. 37.6%). Table 1 also provides a 
summary of the binary logistic regression groups used for statistical analysis as related to the 
sample’s age, surgery, whether they were currently undergoing treatment, and recreational 
exercise levels. 
<INSERT TABLE 1 HERE> 
<INSERT TABLE 2 HERE> 
Side-effects: Descriptive and Relationship Results 
Table 3 provides a summary of the side-effects examined, the number of participants who 
responded to the question (out of a potential 432 participants), the mean of the Likert scores 
in response to each side-effect, and the percentage of the sample who experienced each side-
effect. Hot flushes, sleep disorders, aching muscles and fatigue were the most commonly 
experienced side-effects with approximately two thirds of respondents reporting each (66.3%, 
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65.3%, 64.3% and 62.7%, respectively). Table 4 indicates the significance of each side-effect 
against age, surgery, current treatment and exercise participation, as determined by a binary 
logistic regression with odds ratios (OR) and 95% confidence intervals (95% CI). 
Approximately half of the side-effects (7 of 15) were associated with at least once of the 
independent variables. Weight gain was significantly related to all the independent variables 
except age.   
<INSERT TABLE 3 HERE> 
<INSERT TABLE 4 HERE> 
Side-effects and Surgery: Compared to women who had undergone a mastectomy, women 
who had undergone a lumpectomy were less likely to report fatigue (OR = 0.60; 95% CI 0.38 
- 0.96; p = 0.05), aching muscles (OR = 0.61; 95% CI 0.39 – 0.96; p = 0.023), and weight 
gain (OR = 0.59; 95% CI 0.38-0.92; p = 0.02); while controlling for age, current treatment 
and exercise levels. 
Side-effects and Current Treatment: Compared to women who were finished all treatment, 
women who were still taking medication for their breast cancer were more likely to report 
experiencing weight gain (OR = 1.89; 95% CI 1.19-2.99; p = 0.007), hot flushes (OR = 3.77; 
95% CI (2.34-6.08); p < 0.001) and aching muscles (OR = 1.62; 95% CI 1.02-2.57; p = 
0.031); while controlling for age, surgery type and exercise level. 
Side-effects and Exercise: Compared to women who were sufficiently active, sedentary 
women were more likely to report experiencing weight gain (OR = 2.29; 95% CI 1.44 - 3.64; 
p < 0.001), shoulder limitations OR = 1.77; 95% CI (1.14 – 2.77; p = 0.012), breathlessness 
(OR = 2.30; 95% CI 1.35 - 3.92; p = 0.002), muscular chest wall pain (OR = 1.69; 95% CI 
1.07-2.65; p = 0.023), and arm lymphedema (OR = 1.68; 95% CI 1.04 – 2.71; p = 0.034); 




The present study sought to gain a better understanding of the side-effect experience of 
women following breast cancer treatment. It did so through a binary logistic regression 
analysis of selected patient characteristics against self-reported side-effects. Of 15 listed side-
effects, 7 were significantly associated with at least one patient characteristic, confirming our 
first hypothesis that these characteristics have a moderate association with side-effect 
experience. 
Age 
Age did not emerge as being strongly associated with the side-effects experienced by breast 
cancer survivors, and was not linked to any of the examined side-effects. The study cohort is 
younger than the wider breast cancer population, which may have limited our ability to illicit 
an association with this variable. 
Surgery 
Women who had undergone a mastectomy were more likely to experience aching muscles, 
weight gain and hot flushes than women who had undergone a lumpectomy. Findings from 
previous research regarding relationships between surgery type and symptom experience 
have been mixed. For example, whereas Janz et al. [1] found no clinically meaningful 
differences in symptom experience between women who received a mastectomy and those 
who received breast conserving surgery, Rabin et al. [26] found women who underwent a 
mastectomy indicated lower QOL scores in the physical and psychological domains than their 
breast conserving surgery counterparts. 
The finding of an association between aching muscles and having a mastectomy is not 
unexpected. Pain and numbness in the breast, chest wall, or axilla are common complications 
of breast cancer surgery, affecting 15-75% of survivors, and are often related to the extent of 
surgery performed [2]. 
Unexpectedly, weight gain also emerged as being significantly related to undergoing a 
mastectomy. As a side-effect, weight gain is of particular importance as it can predispose 
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breast cancer survivors to other morbidities, such as cardiovascular diseases and orthopaedic 
problems [27]. Weight gain can also negatively impact upon self-esteem and other 
psychological aspects of QOL [28]. Furthermore, weight gain and obesity have been 
significantly linked to higher relapses and poorer survival [13], arm swelling and symptoms 
of persistent lymphedema [2, 17]. Previous research has indicated that weight gain is more 
common in women receiving adjuvant chemotherapy, particularly for extended treatment 
durations, and appears to be more pronounced in premenopausal women [27]. No research 
could be located which explored the link between specific surgery types and weight gain, 
making this the first study to suggest this association. 
Finding an association between hot flushes and surgery was also unexpected, 
particularly as in the absence of ovarian ablation, the primary treatment responsible for hot 
flushes is adjuvant endocrine therapy, not surgery. Although the binary logistic regression 
model used in this analysis controlled for age and whether women were currently undergoing 
adjuvant endocrine therapy, it was not possible to control for the extent of adjuvant endocrine 
therapy, or menopausal status, which may have influenced this outcome. Nevertheless, it is 
possible that although surgery per se is not responsible for experiencing hot flushes, the 
experience of other adverse events linked to surgery may play a significant role. Particularly, 
correlations between weight gain and experiencing hot flushes exist [29], and given the 
significant association between weight gain and surgery in the present study, it is possible 
these events are inter-related in their link to experiencing hot flushes. Therefore, 
rehabilitation efforts for women post-surgery should also be aware of the associations 
between weight gain and hot flushes, and the risk a greater extent of surgery poses towards 
experiencing these side-effects.  
Current Treatment  
Women who were currently taking medication for their breast cancer were more likely to 
experience hot flushes, weight gain, and aching muscles than women who had completed all 
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breast cancer treatment. However, the finding that 12 of the 15 listed side-effects were not 
significantly associated with treatment completion is also clinically relevant, as it suggests 
that side-effects as a result of treatment can present a lasting burden for some women, due to 
these side-effects being experienced equally by women undergoing treatment, and those who 
are not (average 4.3 years post treatment completion). 
The present study found women were more likely to experience hot flushes while 
currently undergoing breast cancer treatment, which supports previous research suggesting a 
strong link between hot flushes and primary breast cancer treatment [30]. These treatment-
induced hot flushes have been linked to abrupt and premature menopause (among 
premenopausal women) as a result of chemotherapy and ovarian ablation; and commonly 
used adjuvant therapies in breast cancer, such as tamoxifen and aromatase inhibitors [30]. 
Estrogen withdrawal as a result of these treatments is thought to be an initiator of hot flushes, 
as changes in estrogen levels may affect functioning of the thermoregulatory centres in the 
hypothalamus [30]. Up to 65% of women report hot flushes during or following breast cancer 
treatment and 64%-82% of these patients rate these episodes as moderate to severe [31]. In 
the present study hot flushes were the most commonly reported side-effect, experienced by 
66.3% of participants. 
Current breast cancer treatment was also significantly associated with weight gain. 
These results are similar to a study in which one year after treatment began, 62.5% of study 
participants experienced a significant weight gain of 5 pounds (2.27 kg) or more [28]. After 
two years, 68% of those women who gained weight in the initial year maintained a clinically 
significant weight gain. This percentage was reduced to 40% after three years, suggesting, as 
with the present study, that the greatest effect of weight gain was experienced in the initial 
stages of breast cancer treatment. Furthermore, the vast majority of women undergoing 
treatment in the present study were undertaking hormonal therapies (n = 226, which was 95% 
of the women currently undergoing treatment). Decreased serum estradiol levels are a 
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significant factor in weight gain and are commonly linked to hormonal therapies, although 
evidence is mixed [32, 33]. It is likely that menopausal status contributes to inconsistent 
evidence regarding weight gain and hormonal therapies because common treatments such as 
Tamoxifen have both antiestrogenic and estrogenic properties, depending on the natural 
hormonal environment of the target patient [33]. Although menopausal status was not 
controlled for in the present study, the strong association between weight gain and currently 
taking medication, predominantly hormonal therapies, still poses a significant link that health 
professionals who are assisting women in long-term management of their breast cancer 
treatment side-effects need to be aware of. 
Exercise 
Previous research has confirmed that exercise can reduce the burden of some side-effects of 
breast cancer treatment such as fatigue and pain [6], as well as have positive effects on 
physical function, physical capacity, and muscular fitness, during and after cancer treatment 
[12-14]. Confirming our second hypothesis, women who were insufficiently active were more 
likely to experience a range of side-effects, including shoulder limitations, muscular chest 
wall pain, weight gain, lymphedema or breathlessness. Previous research has noted 
improvements in shoulder limitations, weight gain and arm lymphedema among breast cancer 
patients who exercise [34-36], but no research could be located which directly considered the 
side-effects of breathlessness or muscular chest wall pain. 
Upper limb dysfunction, including a reduced range of motion in the shoulder, muscle 
weakness, and pain and numbness, are common postoperative complications for breast cancer 
patients [35, 37]. These dysfunctions not only impact on physical health, as breast cancer 
survivors with clinically defined arm/shoulder problems also have significantly poorer QOL 
than survivors without arm/shoulder pain [9]. A comprehensive Cochrane Review recently 
concluded that “exercise can result in significant and clinically meaningful improvements in 
shoulder ROM [range of motion] in women with breast cancer” [35]. As such, the result that 
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shoulder limitations are less likely to occur among breast cancer survivors who were 
sufficiently active is not surprising. 
Muscular chest wall pain was also significantly associated with not being sufficiently 
active. Pain as a result of breast cancer treatment is an ill-defined syndrome ranging from 
mild pain to significant nociceptive pain and neuromas [38, 39]. Upper-body pain is a 
commonly experienced breast cancer treatment side-effect, and the extent of pain experienced 
is generally linked to more invasive surgery and aggressive radiation treatments [40, 22, 37]. 
Although evidence is limited, commonly-used clinical approaches to upper-body morbidities 
such as muscular chest wall pain include gentle exercises, which promote normal muscular 
recruitment patterns and enhance tissue extensibility [37]. Therefore, it is postulated that 
women who sufficiently exercise, and particularly promote controlled use of pectoralis, 
serratus anterior and latissimus dorsi musculature, would also be less likely to experience 
muscular chest wall pain.  
The present study also found weight gain was significantly related to not being 
sufficiently active. For women undergoing breast cancer treatment, evidence suggests weight 
gain occurs without concurrent gains in lean body mass, and is not caused by overeating but 
rather is a result of reduced physical activity [34]. Previous research concluded that exercise 
is an effective intervention for managing or preventing weight gain in women undergoing 
breast cancer treatment [34], which is consistent with the current finding. 
Arm lymphedema is caused by an accumulation of fluid in interstitial space, and 
occurs in 10 to 25% of women treated for breast cancer [2]. The risk of arm lymphedema is 
directly related to the extent of surgery, or radiation treatment or both [2], and it is regarded 
as a persistent or chronic condition [37]. Even when symptoms appear resolved, a patient 
remains at an increased risk of redeveloping lymphedema [37]. Traditionally, clinicians have 
been cautious with the prescription of exercise, particularly weight lifting, to women who 
may be at risk of developing arm lymphedema, as increases in resistance within the muscle, 
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along with increased blood flow as experienced during exercise, may increase lymph 
production in the arm [37]. However, a recent randomized controlled trial concluded weight 
lifting did not significantly affect arm lymphedema, but rather, resulted in a decreased 
incidence of exacerbations of lymphedema, reduced symptoms, and increased strength [36]. 
Other studies have also concluded no evidence of negative effects from upper-body exercise 
on the incidence of arm lymphedema; and slowly progressive resistance training is protective 
against lymphedema flare-ups among women at risk [41, 14].  These findings agree with the 
present study in that sufficiently active women were less likely to report arm lymphedema. 
Finally, women who were sufficiently active were less likely to report breathlessness 
than their more sedentary counterparts. This may be linked to an improved or maintained 
state of cardio-respiratory fitness. We postulate that breast cancer treatment could itself 
impact upon a patient’s cardio-respiratory system or, alternatively, experiences of other 
treatment-related side-effects, could lead to sedentary behaviours and consequential cardio-
respiratory de-conditioning. Studies examining the effects of exercise during breast cancer 
treatment have concluded that exercise can have a positive influence on cardio-respiratory 
outcomes [12, 13, 42]. Similar to improvements in shoulder limitations, these effects go 
beyond exclusively physical benefits, with cardio-respiratory improvements having also been 
positively correlated with QOL scores in a breast cancer cohort [43]. 
Limitations and Recommendations 
Although a validated survey instrument was used, this study was limited in the use of self-
reported data and by its cross-sectional design, and therefore we cannot draw conclusions 
regarding causality. Furthermore, it was not possible to analyse side-effects against 
chemotherapy or radiotherapy because almost all the women in the study had undergone 
some form of either chemotherapy or radiotherapy, making the split into groups for a binary 
logistic regression unfeasible. This also inhibited an in-depth separation of chemotherapy, 
radiation, and surgical treatments for analysis with respect to the specific side-effects likely to 
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be linked to these specific treatments. Future studies with a larger study population, which 
can draw meaningful sample sizes for exclusive treatment groups, would be required to 
achieve this type of analysis. Health status also provides insight into patient outcomes, and 
future studies should consider including this in analysis. The present study was also limited in 
a lack of menopausal status data for the participants. Considering the mean sample age was 
53 years, it is likely some women were peri-/menopausal. Therefore, it is possible that side-
effect experiences such as weight gain or hot flushes were linked to natural menopause, 
rather than being treatment induced menopausal symptoms. Finally, as most of the sample 
consisted of members of the BCNA Review and Survey group, these women may be more 
motivated to participate in research and were younger than the general Australian breast 
cancer population, which may limit the generalizability of the study results.  
Strengths 
Despite the aforementioned limitations, this study holds much merit as an investigation into 
how patient characteristics and exercise may be associated with self-reported side-effects to 
breast cancer treatment. To our knowledge, this is the largest cross-sectional study on the 
side-effects of breast cancer in an Australian population, and one of the most comprehensive 
lists of self-reported side-effects of breast cancer published to date. The project engaged a 
multi-state and multi-centre recruitment strategy, although it is acknowledged that it was 
limited to women who were part of a support system for their breast cancer. Despite this, the 
sample was closely matched to an Australian population in terms of location spread, health 
status and physical activity levels. Finally, by using an online questionnaire, the study was 
able to randomise the list of side-effects presented in each survey; thereby eliminating any list 
ordering biases, as well as limiting any potential transcription errors during analysis. 
Conclusions 
The objective of this research was to gain a better understanding of breast cancer treatment-
related side-effects through identifying their association with patient characteristics such as 
18 
 
age, type of surgery, whether women were currently undergoing treatment, and exercise 
levels. Given that 7 out of 15 listed side-effects were significantly associated with at least one 
patient characteristic, these characteristics may hold moderate value as potential indictors of a 
greater or lesser side-effect experience, and may therefore be useful when planning 
supportive care following breast cancer treatment. Targeting individuals who are at a high 
risk of developing breast cancer treatment side-effects could help improve the focus of 
resources to those patients most likely to benefit [17]. However, patient characteristics such 
as age, surgery and current treatment are not readily changeable and, while awareness of 
symptom experiences and high-risk groups may assist in better targeting clinical resources, 
deviations from required treatments are limited. On the other hand, exercise was associated 
with a lesser symptom experience for shoulder limitations, muscular chest wall pain, weight 
gain, lymphedema and breathlessness. Combined with the growing body of knowledge 
regarding the positive effects of exercise on QOL and breast cancer survival, this finding 
supports the call for further research into the adherence to, and promotion of, physician-
approved exercise for women living with a breast cancer diagnosis.  
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Table 1: Respondents’ characteristics with comparisons to Australian population data, and 


















New South Wales  114 26.6% 34%
Victoria  119 27.8% 25%
Queensland  65 15.2% 18%
Western Australia  26 6.1% 9%
South Australia  41 9.6% 9%
Tasmania  15 3.5% 2%
Australian Capital Territory  44 10.3% 2%














Age  432   Australian Breast Cancer Population [24]
What is your date of birth? 
<30  2 0.5% 0%
 
  “Under 50 years old” 
n = 144; 33% 30‐49  142 32.9% 12%  
50‐69  271 62.7% 51%
 
  “50 years and over” 











Sufficiently Active  158 37.4% 37.6%     “Sufficiently Active”
Missing data  9   n = 158; 37.6%
   


















Missing data  3 0.7%    
     


























1Two respondents were simultaneously undergoing chemotherapy and hormonal therapies, while 




Table 2: Criteria for classifying women into high, moderate or low levels of physical 
activity; the number of women who met each criterion; and the percentage this was of the 
sample population. 
 





























Total Sample    423  100.00% 
 
1 The number of women calculated in the total ‘high’ and total ‘moderate’ levels of physical activity is not equal 




Table 3: Reported side-effects, the number of participants who responded to the question (out of a potential 432), the Likert scores in response to 

















Hot flushes  398  134  104  77  58  25  2.34 (2.21‐2.46)  66.3% 
Sleep disorders  392  135  116  66  52  23  2.27 (2.14‐2.39)  65.3% 
Aching muscles  392  140  142  65  33  12  2.07 (1.96‐2.17)  64.3% 
Fatigue  399  149  109  82  48  11  2.16 (2.04‐2.27)  62.7% 
Shoulder limitations  392  192  118  58  21  3  1.79 (1.70‐1.88)  51.0% 
Pain  378  189  120  43  23  3  1.76 (1.67‐1.85)  50.3% 
Muscular chest wall pain  379  198  124  33  20  4  1.70 (1.61‐1.79)  47.8% 
Weight gain  390  218  83  47  34  8  1.80 (1.69‐1.91)  44.1% 
Depression  390  222  90  49  21  8  1.73 (1.63‐1.83)  43.1% 
(Arm) Lymphedema  388  257  87  33  9  2  1.48 (1.41‐1.56)  33.8% 
Burning/sensitive skin/chafing  370  248  74  31  13  4  1.52 (1.43‐1.61)  33.0% 
Breathlessness  378  274  65  27  8  4  1.42 (1.34‐1.50)  27.8% 
Other  190  153  12  9  11  5  1.44 (1.29‐1.58)  20.0% 
Nausea  367  303  35  14  11  4  1.31 (1.23‐1.38)  17.7% 





Table 4: Reported side-effects according to mean score; and significance of reported side-effects by age, surgery, currently undergoing treatment 















Hot flushes  0.97  (0.59‐1.61)  0.60*  (0.38‐0.96)  3.77**  (2.34‐6.08)  0.97  (0.60‐1.59) 
Sleep disorders  0.69  (0.43‐1.10)  0.80  (0.51‐1.25)  1.41  (0.89‐2.24)  1.36  (0.86‐2.15) 
Aching muscles  0.87  (0.54‐1.40)  0.61*  (0.39‐0.96)  1.62*  (1.02‐2.57)  1.04  (0.65‐1.66) 
Fatigue  1.22  (0.77‐1.95)  0.89  (0.57‐1.38)  1.50  (0.96‐2.35)  1.46  (0.93‐2.29) 
Shoulder limitations  1.14  (0.73‐1.79)  0.74  (0.48‐1.14)  1.02  (0.66‐1.60)  1.77*  (1.14‐2.77) 
Pain  1.33  (0.84‐2.10)  0.90  (056‐1.39)  1.05  (0.67‐1.64)  1.41  (0.90‐2.20) 
Muscular chest wall pain  1.06  (0.67‐1.66)  0.71  (0.46‐1.10)  1.53  (0.97‐2.40)  1.69*  (1.07‐2.65) 
Weight gain  1.40  (0.88‐2.22)  0.59*  (0.38‐0.92)  1.89**  (1.19‐2.99)  2.29**  (1.44‐3.64) 
Depression  1.06  (0.68‐1.67)  1.13  (0.74‐1.74)  1.07  (068‐1.68)  1.48  (0.95‐2.32) 
(Arm) Lymphedema  1.00  (0.62‐1.61)  0.92  (0.59‐1.46)  1.38  (0.86‐2.22)  1.68*  (1.04‐2.71) 
Burning/sensitive 
skin/chafing 
1.07  (0.65‐1.73)  1.15  (0.72‐1.83)  1.50  (0.91‐2.46)  1.44  (0.88‐2.35) 
Breathlessness  1.12  (0.68‐1.85)  1.01  (0.62‐1.63)  0.82  (0.50‐1.34)  2.30**  (1.35‐3.92) 
Other  0.88  (0.39‐2.03)  0.91  (0.41‐2.00)  1.83  (0.80‐4.21)  1.34  (0.59‐3.06) 
Nausea  1.39  (0.77‐2.48)  1.04  (0.58‐1.84)  1.84#  (0.98‐3.47)  1.13  (0.62‐2.04) 
Broken/painful ribs  1.21  (0.66‐2.24)  1.03  (0.56‐1.87)  1.02  (0.55‐1.91)  1.68  (0.88‐3.24) 
* p < 0.05 
** p < 0.01 
 
